AL amyloidosis associated with IgM paraproteinemia: Clinical profile and treatment outcome

Blood

Volumn 112, Issue 10, 2008, Pages 4009-4016

  Wechalekar, Ashutosh D ^a   Lachmann, Helen J ^a   Goodman, Hugh J B ^a   Bradwell, Arthur ^b   Hawkins, Philip N ^a   Gillmore, Julian D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IDARUBICIN; IMMUNOGLOBULIN M; LOMUSTINE; MELPHALAN; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE; ALKYLATING AGENT; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; AL AMYLOIDOSIS; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CELL INFILTRATION; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HEART; HUMAN; KIDNEY; LIGHT CHAIN; LYMPH NODE; LYMPHOID CELL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARAPROTEINEMIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL; TREATMENT RESPONSE; UNITED KINGDOM; ANTIBODY SPECIFICITY; BLOOD; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALKYLATING AGENTS; AMYLOIDOSIS; DISEASE-FREE SURVIVAL; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; ORGAN SPECIFICITY; PARAPROTEINEMIAS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 57349197967     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-138156     Document Type: Article

References (47)

1. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79:1817-1822.
2. Swan N, Skinner M, O'Hara CJ. Bone marrow core biopsy specimens in AL (primary) amyloidosis. A morphologic and immunohistochemical study of 100 cases. Am J Clin Pathol. 2003;120: 610-616.
3. Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78-84.
4. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45-59.
5. Kyle RA, Vincent Rajkumar S. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134:573-589.
6. Baldini L, Goldaniga M, Guffanti A, et al. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system. J Clin Oncol. 2005;23:4662-4668.
7. Gertz MA, Kyle RA, Noel P. Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenstrom's macroglobulinemia. J Clin Oncol. 1993; 11:914-920.
8. Gertz MA, Kyle RA. Amyloidosis with IgM monoclonal gammopathies. Semin Oncol. 2003;30: 325-328.
9. Valente M, Roy V, Lacy MQ, Dispenzieri A, Gertz MA. Autologous stem cell transplantation and IgM amyloidosis. Leuk Lymphoma. 2006;47:1006-1012.
10. Cohen AD, Zhou P, Xiao Q, et al. Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. Br J Haematol. 2004;124:309-314.
11. Röcken C, Schwotzer EB, Linke RP, SaegerW. The classification of amyloid deposits in clinicopathological practice. Histopathology. 1996;29:325-335.
12. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346:1786-1791.
13. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
14. Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med. 1990;323:508-513.
15. Weber D, Treon SP, Emmanouilides C, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30:127-131.
16. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437- 1444.
17. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005;79:319-328.
18. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649- 655.
19. Gertz MA, Kyle RA, Greipp PR. Hyposplenism in primary systemic amyloidosis. Ann Intern Med. 1983;98:475-477.
20. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354: 1362-1369.
21. Dacic S, Colby TV, Yousem SA. Nodular amyloidoma and primary pulmonary lymphoma with amyloid production: a differential diagnostic problem. Mod Pathol. 2000;13:934-940.
22. Goteri G, Ranaldi R, Pileri SA, Bearzi I. Localized amyloidosis and gastrointestinal lymphoma: a rare association. Histopathology. 1998;32:348- 355.
23. Gupta D, Shidham V, Zemba-Palko V, Keshgegian A. Primary bilateral mucosa-associated lymphoid tissue lymphoma of the breast with atypical ductal hyperplasia and localized amyloidosis: a case report and review of the literature. Arch Pathol Lab Med. 2000;124:1233-1236.
24. Kambouchner M, Godmer P, Guillevin L, Raphael M, Droz D, Martin A. Low grade marginal zone B cell lymphoma of the breast associated with localised amyloidosis and corpora amylacea in a woman with long standing primary Sjogren's syndrome. J Clin Pathol. 2003;56:74-77.
25. Lim JK, Lacy MQ, Kurtin PJ, Kyle RA, Gertz MA. Pulmonary marginal zone lymphoma of MALT type as a cause of localised pulmonary amyloidosis. J Clin Pathol. 2001;54:642-646.
26. Moriyama E, Yokose T, Kodama T, et al. Lowgrade B-cell lymphoma of mucosa-associated lymphoid tissue in the thymus of a patient with pulmonary amyloid nodules. Jpn J Clin Oncol. 2000;30:349-353.
27. Nakamura N, Yamada G, Itoh T, et al. Pulmonary MALT lymphoma with amyloid production in a patient with primary Sjogren's syndrome. Intern Med. 2002;41:309-311.
28. Odell EW, Lombardi T, Shirlaw PJ, White CA. Minor salivary gland hyalinisation and amyloidosis in low-grade lymphoma of MALT. J Oral Pathol Med. 1998;27:229-232.
29. Setoguchi M, Hoshii Y, Takahashi M, Tanaka T, Nishida T, Ishihara T. Conjunctival AL amyloidosis associated with a low-grade B-cell lymphoma. Amyloid. 1999;6:210-214.
30. Wieker K, Rocken C, Koenigsmann M, Roessner A, Franke A. Pulmonary low-grade MALT-lymphoma associated with localized pulmonary amyloidosis: a case report. Amyloid. 2002;9:190-193.
31. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochimica et Biophysica Acta. 2005;1753:11-22.
32. Lin P, Hao S, Handy BC, Bueso-Ramos CE, Medeiros LJ. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol. 2005;123:200-205.
33. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85-93.
34. Anagnostopoulos A, Hari PN, Perez WS, et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant. 2006;12: 845-854.
35. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003; 349:2495-2502.
36. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202-1207.
37. Offer M, Wechalekar AD, Goodman HJB, et al. Standard oral melphalan chemotherapy for AL amyloidosis revisited using the serum free light chain assay [abstract]. Blood. 2005;106:3495.
38. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109:457-464.
39. Goodman H, Wechalekar A, Lachmann H, Bradwell A, Hawkins P. Clonal diseaes response and clinical outcome in 229 patients with AL amyloidosis treated with VAD-like chemotherapy [abstract]. Haematologica. 2005;90:201.
40. Goodman HJB, Lachmann HJ, Bradwell AR, Hawkins PN. Intermediate dose intravenous melphalan and dexamethasone treatment in 144 patients with systemic AL amyloidosis [abstract]. ASH Annual Meeting Abstracts. 2004;104:755.
41. García-Sanz R, Montoto S, Torrequebrada A, et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115:575-582.
42. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:243-247.
43. Dimopoulos MA, O'Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med. 1993;95:49-52.
44. Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia. Clin Lymphoma. 2002;3:163-166.
45. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006;107:3378-3383.
46. Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of haematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica. 2007;92:1415-1418.
47. Lachmann HJ, Wechalekar AD, Gillmore JD. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis [letter]. N Engl J Med. 2008;358:91-92; author reply: 2008;358:92-93.